ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Program Advocates, Success Overcame Powerful Negative Factors To Win Budget Fight

August 10, 1979

NCI Halts Routine P01 Site Visits Due to Travel Cut

February 7, 1992

Phase III Avastin Trial Fails Primary Endpoints

February 28, 2014

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

Quality Oncology Wins Pilot Contract For Cancer Management In Fla.

July 27, 2001

In Brief: Margaret Sloan, Pioneer In International Medicine Collaboration, Dies; Hammer To Address AACI

January 1, 1982